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Background: Adolescence is a period of change, which coincides with disease remission in a significant proportion
of subjects with childhood asthma. There is incomplete understanding of the changing characteristics underlying
different adolescent asthma transitions. We undertook pathophysiological characterization of transitional adolescent
asthma phenotypes in a longitudinal birth cohort.
Methods: The Isle of Wight Birth Cohort (N = 1456) was reviewed at 1, 2, 4, 10 and 18-years. Characterization included
questionnaires, skin tests, spirometry, exhaled nitric oxide, bronchial challenge and (in a subset of 100 at 18-years)
induced sputum. Asthma groups were “never asthma” (no asthma since birth), “persistent asthma” (asthma at age 10
and 18), “remission asthma” (asthma at age 10 but not at 18) and “adolescent-onset asthma” (asthma at age 18 but
not at age 10).
Results: Participants whose asthma remitted during adolescence had lower bronchial reactivity (odds ratio (OR) 0.30; CI
0.10 -0.90; p = 0.03) at age 10 plus greater improvement in lung function (forced expiratory flow 25-75% gain: 1.7 L;
1.0-2.9; p = 0.04) compared to persistent asthma by age 18. Male sex (0.3; 0.1-0.7; p < 0.01) and lower acetaminophen
use (0.4; 0.2-0.8; p < 0.01) independently favoured asthma remission, when compared to persistent asthma. Asthma
remission had a lower total sputum cell count compared to never asthma (31.5 [25–75 centiles] 12.9-40.4) vs. 47.0
(19.5-181.3); p = 0.03). Sputum examination in adolescent-onset asthma showed eosinophilic
airway inflammation (3.0%, 0.7-6.6), not seen in persistent asthma (1.0%, 0–3.9), while remission group had the lowest
sputum eosinophil count (0.3%, 0–1.4) and lowest eosinophils/neutrophils ratio of 0.0 (Interquartile range: 0.1).
Conclusion: Asthma remission during adolescence is associated with lower initial BHR and greater gain in small
airways function, while adolescent-onset asthma is primarily eosinophilic.Introduction
Remission, and occasionally relapse, of symptoms is ob-
served in many asthmatics over the life course [1-4].
Adolescence is a period of change that is associated with
puberty and rapid physical growth. Clinical remission of
asthma is highest during this period [1], and typically de-
fined as those with a previous diagnosis of asthma who are
asymptomatic at a subsequent assessment without the
need for treatment for a period of at least 12 months
[2-4]. The rate of asthma remission during adolescence
has been variably reported to range from 30 to 65% [4-7].* Correspondence: sha@soton.ac.uk
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unless otherwise stated.Individuals with clinical asthma remission have been
shown to have persistent subclinical disease, characterized
by low lung function, bronchial hyper-responsiveness
(BHR), airway inflammation or remodeling [2,8,9]. How-
ever, characteristics of airway inflammation might be dif-
ferent in those with remittent compared to persistent
asthma. Moreover, changes and risk factors during adoles-
cence that lead to remission of symptoms remain unclear.
There is another group of children who acquire asthma
for the first time at this age. In the Tucson birth cohort,
27% (49 of 181) of asthma at 22 years developed after
16 years of age, although some had wheezed during early
childhood [10]. We have recently reported that in the Isle
of Wight birth cohort, 28% of asthma at age 18 was
of adolescent-onset [11]. Both puberty and lung growth
have been suggested as factors determining asthmaLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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sociated with variable immune response resulting in dif-
ferent types or degree of airway inflammation.
Asthma can be regarded as a diverse syndrome with
varying clinical and pathophysiological characteristics
that may influence disease natural history and outcome
during adolescence. Our overall hypothesis was that sig-
nificant and distinct changes in the pathophysiology of
asthma occur during remission of existing asthma or
development of new asthma during adolescence. The
primary aim was to investigate the pathophysiological
characteristics associated with adolescent asthma tran-
sitions. Study of these characteristics and risk factors
would highlight important differences between these
groups and provide insights into the management and
prevention of asthma during that critical phase in life.
Using data and samples from the Isle of Wight birth
cohort, we explored the “changing face” of asthma
during adolescence.
Research questions
1. What are the pathophysiological characteristics
associated with persistence of asthma during
adolescence? To investigate this, we compared
asthma remission with persistent asthma.
2. What are the factors associated with asthma
remission? To investigate this we tested early life
and adolescent factors relevant to asthma.
3. What are the residual pathophysiological
abnormalities in remittent asthmatics while
symptoms have improved? To investigate this, we
compared asthma remission with never asthma at
age 18 years.
4. What are the pathophysiological characteristics of
asthma that develops during adolescence? To
investigate this, we compared adolescent-onset
asthma with never asthma and persistent asthma.
The Isle of Wight cohort, with its population-based pro-
spective design and extensive phenotyping over the entire
childhood period provides a powerful means of ap-
proaching these questions.
Materials and methods
A whole population birth cohort was established on the
Isle of Wight in 1989 (n = 1456). These children have
been followed at the ages of 1, 2, 4, 10 and 18 years
[13-18]. All participants provided informed consent and
ethical approval was obtained from the Isle of Wight,
Portsmouth and Hampshire Local Research Ethics
Committee (06/Q1701/34). At 10 and 18 years, validated
questionnaires were completed from face to face interview
(those who attended the Centre) or telephone or postalquestionnaires (Additional file 1: Table S1). Participants
attending the Centre in person also underwent spirometry,
assessment of bronchial hyper-responsiveness (BHR), frac-
tional exhaled nitric oxide (FeNO) measurement and skin
prick test (SPT). Details of questionnaires and methods
for SPT, spirometry, BHR and FeNO have been reported
previously [11,17,18].
Briefly, both study-specific and International Study of
Asthma and Allergies in Childhood questionnaires were
completed for detailed assessment of asthma symptoms
and its treatment. Information on environmental risk fac-
tors was collected from birth up to age 18 years such as
birth weight, method of feeding, current and past cigarette
smoking, pets and socio-economic class. At 18-years,
study participants reported average monthly use of acet-
aminophen and NSAID (non-steroidal anti-inflammatory
drugs) during the past year.
For spirometry, American Thoracic Society (ATS)
guidelines were followed to ensure validity and reprodu-
cibility using the Koko system (Koko Spirometer Long-
mont, CO, USA) [19]. To adjust for sex and height
effect on FEV1, FVC, and FEF25–75, we regressed these
variables on sex and height; the residuals with sex and
height effect excluded were used in the analyses. We
used this approach in preference to using % predicted
lung function values. With % predicted values, people
with the same sex and height would register the same
value of % predicted estimated from existing formulas
based on reference populations. Those reference ranges
may not be applicable to our population and would not
necessarily reflect the measure of lung function for each
individual participant in our cohort. Methacholine
bronchial challenge was performed using the protocol
recommended by the ATS [20]. To perform spirometry
or bronchial challenge, participant were required to be
free from respiratory infection for 14 days, not taking
oral steroids, not taken beta2 agonist for 6 hours and
abstained from caffeine intake for at least 4 hours. BHR
was determined by methacholine concentration causing
a 20% fall in FEV1 from the post-saline value, expressed
as PC20 with a positive test defined by PC20 < 8 mg/ml.
A continuous dose–response slope (DRS) measure of
BHR was estimated by least-square regression of per-
centage change in FEV1 upon each successive incre-
mental dose of methacholine administered for each
child. A transformation of Log10 (DRS+ 10) was required
to satisfy the distributional assumption of normal data
with higher positive values signifying greater bronchial re-
activity. We used a continuous dose–response measure of
BHR since not all subjects who undergo bronchial provo-
cation testing will demonstrate a 20% fall in FEV1 that en-
ables calculation of a PC20 to indicate BHR. Reliance on
PC20 would have meant that a proportion of subjects
would not provide meaningful data on BHR. FeNO was
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according to ATS recommendations [21]. Measurements
were made before spirometry testing with the subject
standing without a nose clip. SPT was performed to a
panel of common food/aeroallergens (house dust mite,
grass pollen mix, tree pollen mix, cat, dog, Alternaria
alternata, Cladosporium herbarum, milk, hens’ egg,
wheat, soya, cod and peanut) using allergen extract from
ALK-Abello (Horsholm, Denmark). SPT was regarded as
positive when the mean of the largest diameter plus its
perpendicular was at least 3 mm larger than the negative
control. Subjects with one or more positive SPT were
regarded as atopic.
The 18 year follow-up for the birth cohort was done in
two stages. In phase 1, subjects completed question-
naires and had skin test and lung function test during
the first visit (as described above). The working defin-
ition of asthma at both 10 and 18 years was “physician
diagnosed asthma” and “wheezing or asthma treatment
in the last 12 months”. We then identified subjects who
belonged to the four adolescent asthma groups based on
the following criteria. “Remission” was defined as having
asthma at age 10 but no asthma at age 18 years (absence
of asthma symptoms or medication for 12 months).
“Persistence” was defined as having asthma at both 10
and 18 years. Adolescent-onset asthma was defined as
asthma at age 18 but not at age 10 years. The reference
group of “never asthma” consisted of participants who
did not report wheeze or were given a diagnosis of
asthma at any follow-up (1, 2, 4, 10 and 18 years). Thus,
participants who reported wheeze or asthma at 1, 2 and
4 years but lost symptoms at age 10 were excluded from
the current analysis. In phase 2, from each group
(asthma remission, persistent asthma, adolescent-onset
asthma and never asthma), subjects were randomly se-
lected to undergo sputum induction (n = 100). Subjects
from each group were invited to attend in sequence, ac-
cording to their study number, for a second visit when
sputum induction was performed using a standard
protocol [22]. We stopped, once the required number of
around 20 in remittent asthma and adolescent onset
asthma groups and around 30 in persistent and never
asthma were reached (the latter 2 groups being larger in
size then the former two groups). Following baseline
spirometry, 400 μg salbutamol was administered with
spirometry repeated after 10 minutes. If FEV1 was ≥60%
predicted, participants received serial nebulization of
hypertonic saline (4.5%) for 5 minutes up to a maximum
of 20 minutes (5 × 4). Sputum samples were collected
and immediately placed on ice and processed within
2 hours. Sputum plugs and obvious mucoid components
were selected from the expectorate and weighed. 22.5 μL
of protease inhibitor per gram of sputum and DTT was
added at 4 times the weight of sputum. The sample wasthen placed on a cell rocker for 45 minutes before being
sieved through a sterile nylon mesh. This was then cen-
trifuged for 10 minutes (1500 rpm). The supernatant
was then separated and frozen at −80°C. Total and dif-
ferential cell counts (epithelial cells, lymphocytes, eosin-
ophils, basophils, macrophages and neutrophils) were
recorded. The cellular compositions are presented as a
percent of inflammatory cell type (n) to that of total cell
count (N). Eosinophilic cationic protein was measured
using MESACUP ECP TEST ELISA kit (MBL, CAltag-
Medsystem, Buckinghamshire, UK) following manufac-
turer’s instructions.
Statistical analysis
Data were entered into SPSS version 17 (IBM statistics).
Categorical variables were assessed using Pearson’s chi-
square tests. For continuous measures which passed the
test of normality with or without transformation, we re-
port mean values and independent samples t tests were
applied for comparison. For variables demonstrating
non-normal distributions such as sputum differential
count, median values (with 25th and 75th centiles) are
reported and compared using Mann–Whitney U test. A
multivariate logistic regression model was employed to
assess independent significance of these factors. All vari-
ables showing a trend for significance (p < 0.1) in univar-
iate tests were included in the multivariate model. Two
multiple logistic regression models were created, one
using predictive factors only (present from birth until
age 10 years) and a final model using all factors that
showed suggestive associations (p < 0.1) at univariate risk
factor analysis. A p-value <0.05 was taken to indicate
statistical significance.
Results
At 10 years, 94.3% (1373/1456) and at 18 years, 90.2%
(1313/1456) of the cohort subjects were assessed with
questionnaires. Information on asthma status at both 10
and 18-years was available for 1234 of 1456 (84.8%).
Approximately 70% and 60% participants attended the
Research Centre at 10 and 18 years respectively for full
assessments including SPT, spirometry and methacho-
line bronchial challenge (Additional file 1: Table S1).
Those attending the Centre for full data collection at 10
and 18 years did not differ in key characteristics from
the overall study population [11,18].
Clinical remission during adolescence occurred in
31.0% (56/181) of subjects with asthma at the age of
10 years, while the rest (125) had persistent asthma to age
18 years. Of participants with asthma at 18-years who also
had data at 10-yrs, 36.9% (73/198) had adolescent-onset
asthma. Of 100 participants who underwent sputum in-
duction and processing at age 18 years, spirometry was
available in 98, differential count in 76 and supernatant
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Characteristics of subjects who had sputum induction in
each asthma group were compared to the whole group to
ensure that major characteristics were similar (Additional
file 1: Table S2). Those who underwent sputum induction
were not significantly different from the population from
which they were drawn in various asthma-related cha-
racteristics. As an internal validation, we first compared
atopic subjects with non-atopic and those with and with-
out asthma to confirm their respective characteristics. As
expected, atopic subjects had higher BHR and FeNO as
well as sputum eosinophils, indicating the presence of
underlying (eosinophilic) airway inflammation (Additional
file 1: Table S3). Those with current asthma at age 18 years
(persistent asthma and adolescent-onset asthma) had
significantly lower FEV1 and higher BHR and FeNO
than those without current asthma (asthma remission
and never asthma). Eosinophil count and ECP were also
significantly higher in asthmatics (Additional file 1:
Table S4). Physical measures of height, weight and BMI
were similar between groups over adolescence with and
without gender stratification (data not shown).
1. Comparison of asthma remission with persistent
asthma: to identify characteristics associated with


















% (n/NAt age 10 years: Asthma remission had less atopy
(p = 0.01), current treatment (p = 0.002) and sleep
disturbance (p = 0.04) than the persistent asthma
(Table 1). Moreover, at this age, children destined
for asthma remission had significantly lower BHR
than those with persistent asthma (Figure 1a).e 1 Asthma characteristics at age 10 years in adolescents w
s
Remission % (n/N) Persisten
ent wheeze (>4/year) 38 (17/45) 50 (54/10
sounded wheezy with exercise 57 (32/56) 70 (87/12
affected by wheeze 57 (28/49) 48 (52/10
affected (≥1/week) 4 (2/49) 16 (17/10
zing severe enough to limit speech 13 (7/55) 15 (18/12
ough at night apart from a cold or
infection
54 (30/56) 65 (80/12
rrent asthma treatment 76 (42/55) 93 (114/1
haled steroids at age 10 39.3 (22/56) 30.7 (35/
43 (20/47) 70 (73/10
ze 89 (50/56) 88 (110/1
is 46 (25/55) 53 (64/12
:
s are percentage (numbers affected / total number). They refer to the previous
r assessment.
arisons in this table were made using Pearson’s chi-square test, with two sided s
) percentage, where n is the number of participants with the specific symptomDuring adolescence: As adolescence is a period of
growth and changes in lung function may occur
differently in boys and girls, we stratified for sex,
when analyzing spirometric data for changes during
adolescence. Gain in lung function during
adolescence (difference between 10 and 18 years)
was higher in boys with asthma remission compared
to persistent asthma for both FEV1 [2.6 L (SE: 0.1)
versus 2.4 L (0.1); p: 0.04] and FEF25–75% [2.7 L (0.2)
versus 2.1 L (0.1); p = 0.005). Similar improvements
in pulmonary function of remittent females did not
reach statistical significance (Table 2).
At age of 18-years: Children with asthma remission
continued to have significantly lower BHR at age
18 years. As expected their lung function was higher
and FeNO lower, as they had now lost all symptoms
(Table 3 and Figure 1b).
2. Early life and adolescent risk factors:; to identify
factors associated with asthma remission. Tables 4
and 5 show factors associated with asthma remission
at univariate level. When adjusted for other factors,
male sex and BHR at age 10 showed independent
significance in the predictive model (Table 6). The
final model demonstrated significance for gain in
small airway function towards asthma remission, in
addition to lower use of acetaminophen during
adolescence and lack of rhinitis at 18 years (Table 6).
3. Comparison of asthma remission with never asthma
at age 18; to identify residual pathophysiological
abnormalities in remittent asthmatics while
symptoms have improved. We found a low total cell
count (median: 31.5, 25–75 centiles: 12.9-40.4) inhose asthma remitted or persisted between 10 and 18
t % (n/N) Odds ratio 95% Confidence interval p-value
8) 0.6 0.3 – 1.2 0.17
5) 0.6 0.3 – 1.1 0.10
8) 1.4 0.7 – 3.0 0.30
8) 0.2 0.1 – 0.9 0.04
2) 0.8 0.3 – 2.1 0.72
4) 0.6 0.3 – 1.2 0.16
23) 0.2 0.1 – 0.6 0.002
114) 0.7 0.4 – 1.3 0.2
4) 0.4 0.2 – 0.8 0.01
25) 1.1 0.4 – 3.1 0.80
1) 0.7 0.4 – 1.4 0.36
year apart from atopy, which is defined as any positive skin prick test at
ignificance set at p <0.05.
s and N is the total number in that group.
Figure 1 Bronchial reactivity for adolescent asthma transition groups (remission versus persistent) at 10 and 18 years (a and b).
Children who go into remission during adolescence had lower bronchial hyperresponsiveness than persistent asthma at 10 years (when they still
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compared to never asthma (47.0, 19.5-181.3;
p = 0.03), even though both groups were
asymptomatic at age 18, were not taking inhaled
steroids, and their FEV1, BHR and FeNO were not
significantly different.
4. Comparison of adolescent-onset asthma with persistent
asthma; to investigate the characteristics of asthma that
develops during adolescence. Adolescent-onset asthma
demonstrated sputum eosinophilia (3.00%, 0.7-6.6),
which was not present in persistent asthma (1.0%,
0–3.9). However, there were no statistically significantble 2 Height adjusted pulmonary function: Gain in spirome
mission and persistence
Remission Persistent
ale n = 17 n = 40
V1 (L) (S.E.) 2.6 (0.1) 2.4 (0.1)
C (L) (S.E.) 2.3 (0.1) 2.3 (0.0)
F25–75% (L/s) (S.E.) 2.7 (0.2) 2.1 (0.1)
male n = 7 n = 45
V1 (L) (S.E.) 1.4 (0.1) 1.3 (0.1)
C (L) (S.E.) 3.0 (0.1) 3.1 0.1)
F25–75% (L/s) (S.E.) 1.3 (0.2) 1.3 (0.1)
tes:
neral Linear Model (GLM) for remission of asthma to persistent asthma. Estimate
) represents number of participants that provided information.
V1 = Forced expiratory volume in first second in liters (L) with standard error (S.E.
C = Forced vital capacity in liters (L) with standard error (S.E.).
F25–75% = Forced expiratory flow 25 to 75% in liters per second (L/s) with standarddifferences in physiological or pathological characteris-
tics or in treatment among the two adolescent asthma
groups (Figure 2).
Eosinophils/neutrophils ratio
Adolescent-onset asthma had higher eosinophil count
(3.0%, 0.7-6.6) than never asthma (0.3%, 0–1.3); p = 0.005.
Among asthma groups, asthma remission had the lowest
sputum eosinophil count (0.3%, 0–1.4), similar to never
asthma. We used the ratio of sputum eosinophils/
neutrophils as a marker of the type of inflammation in
different groups. As expected, atopics had a higher ratiotric function from 10 to 18 years in those with asthma
Odds ratio 95% Confidence interval p-value
0.2 0.0 to 0.5 0.04
0.1 - 0.0 to 0.3 0.44
0.6 0.2 to 1.0 0.005
0.1 - 0.2 to 0.4 0.43
- 0.1 - 0.4 to 0.2 0.67
0.1 - 0.5 to 0.6 0.86
d marginal means used for determination of height adjusted means.
).
error (S.E.).
Table 3 Characteristics of asthma remission and persistent asthma at age 18 years
Asthma remission Persistent asthma p-value
FEV1 (L) Mean (SD) 4.2 (0.7) 3.9 (0.8) 0.04
N = 30 96
BHR (DRS) Mean (SD) 1.1 (0.2) 1.4 (0.5) <0.001
N = 33 67
FeNO (ppb) Mean (SD) 27.2 (28.8) 56.3 (54.5) 0.002
N = 25 60
Atopy % (n) 40.6 (13) 76.6 (72) <0.001
N = 32 94
Sputum data N = 16 N = 22
Total cell count Median 31.5 38.0 0.41
(25–75 centiles) (12.9-40.4) (11.8-66.0)
% Epithelial cells Median 5.4 7.6 0.28
(25–75 centiles) (1.4-11.1) (3.3-13.8)
% Neutrophils Median 20.0 11.5 0.09
(25–75 centiles) (8.3-40.8) (5.5-24.3)
% Eosinophils Median 0.3 1.0 0.48
(25–75 centiles) (0–1.4) (0-3.9)
ECP (ng/ml) 35.5 119.5 0.09
(25–75 centiles) (18.7-229.6) (65.4-279.6)
Notes:
FEV1 was adjusted for height and sex.
Means were compared using two sample T test. Pearsons chi-square test was used to compare differences in proportion. Non-parametric test (Mann–Whitney U
test) was used to compare medians in the samples with non-normal distribution. Two sided significance was set at p <0.05.
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atopic (0.0, 0.1; p = 0.002). Similarly, those with asthma
also had a higher ratio (0.2, 0.6), compared to those with-
out at age 18 (0.0, 0.1; p = 0.02). Among asthma groups,
the asthma remission had the lowest eosinophils/neutro-
phils ratio of 0.0 (0.1). Adolescent-onset asthma had a sig-
nificantly higher eosinophils/neutrophils ratio (0.3, 0.8)
compared to never asthma (0.0, 0.1; p = 0.004) and a trend
to be high when compared to persistent asthma (0.1, 0.4;
p = 0.09).
Discussion
Adolescents reporting remission of their asthma by age
18 had less BHR at 10 and demonstrated a higher gain
in airway function during adolescence compared to per-
sistent asthmatics. They also showed low FeNO and cel-
lular paucity in their airways at age 18, especially of
eosinophils with the lowest eosinophil/neutrophil ratio
among all groups, including never asthma. Lower use of
acetaminophen was the only environmental factor asso-
ciated with remission amongst multiple factors assessed
from birth to adolescence. The adolescent-onset asthma
showed prominent eosinophilic inflammation.
The strengths of our study include prospective follow-
up from birth, extensive phenotyping including standard-
ized questionnaires on asthma morbidity and treatment,and objective assessments of atopy, lung function and
airway inflammation. Thus, our reference group of never
asthma had no asthma or wheeze since birth, avoiding
misclassification in diagnosis. There are some limitations
to this study, such as the relatively small number of
subjects who had sputum induction. As a result, some
comparison lacked adequate power and may have resulted
in false negatives statistics. For example, the subgroup
who underwent sputum induction was disproportionately
male with higher atopy and FeNO levels. Further,
adolescent-onset asthma had a 3-fold higher sputum
eosinophilia than persistent asthma, or ECP was more
than 3 fold higher in persistent asthma compared to
asthma remission but neither of these reached statistical
significance. Thus, we suggest that sputum findings
should be treated with caution. We also did not have
bronchial biopsy or peripheral blood differential counts
to compare to the pattern of inflammatory cells seen in
sputum.
It is widely acknowledged that some patients with
clinical remission of asthma do have persistent BHR and
airway inflammation [2,8,9,23]. This is important to
recognize in order to understand the biological process
behind remission and to estimate the risk of recurrence in
future. Some investigators have used the term “complete
remission” to identify the sub-group of clinically










Male 68 (38/56) 53 (66/125) 1.9 1.0 – 3.6 0.06
Low Birth Weight$ 8 (4/53) 5(6/123) 1.6 0.4 – 5.9 0.49
Pre-term delivery* 2 (1/53) 2 (2/123) 1.1 0.1 – 13.1 0.90
Maternal asthma 21.2 (11/52) 30.6 (37/121) 1.6 0.8 – 3.5 0.14
Paternal asthma 11.5 (6/52) 21.5 (26/121) 2.1 0.8 – 5.4 0.09
Recurrent chest infections up to 2 years of age 37 (15/41) 32 (31/98) 1.2 0.6 – 2.7 0.57
Less than 4 months breast feeding 78 (36/46) 65 (72/111) 2.0 0.9 – 4.4 0.10
Formula feeding in first 4 months of life 83 (38/46) 73 (80/109) 0.6 0.2 – 1.4 0.22
Maternal smoking during pregnancy 27 (15/55) 19 (24/124) 1.6 0.7 – 3.3 0.24
Overweight at 10 16.3 (7/43) 23.9 (26/109) 1.6 0.6 – 4.0 0.21
Atopy at 4 42 (16/38) 58 (54/94) 0.5 0.3 – 1.2 0.11
Atopy at 10 43 (20/47) 70 (73/104) 0.4 0.2 – 0.8 0.01
Wheeze at 1 or 2 46 (19/41) 37 (36/98) 1.5 0.7 – 3.1 0.29
Wheeze at 4 63 (32/51) 60 (64/107) 1.1 0.6 – 2.3 0.72
Wheeze at 10 89 (50/56 88 (110/125) 1.1 0.4 – 3.1 0.80
Asthma at age 4 52 (26/50) 56 (59/106) 0.9 0.4 – 1.7 0.67
Rhinitis at 1or 2 25 (11/44) 19 (19/98) 1.0 0.4 – 2.5 0.95
Rhinitis at age 4 15 (8/53) 17 (17/103) 1.0 0.4 – 2.5 1.00
Rhinitis at age 10 46 (25/55) 53 (64/121) 0.7 0.4 – 1.4 0.36
BHR Positive** 51.3 (20/39) 75.2 (79/105) 0.3 0.1 – 0.7 0.006
General Terms.
% (n/N) percentage determined from number of participants with condition/total number of participants with available information on the variable.
Specific Terms.
$Low birth weight: <2.5Kg* Pre-term delivery was defined as delivery of child in less than 37 complete weeks of gestation.
**PC20<8mg/ml.
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obstruction [5]. However, it is hard to define
“complete” as this may depend on how extensively
one looks for signs of persistent disease. For example,
airway inflammation and increased basement mem-
brane thickness was found in those with “complete
remission” defined as clinical remission plus lack of
BHR [24]. We studied clinical remission from a longi-
tudinal perspective to identify its risk and predictiveTable 5 Adolescent factors for remission of asthma
Asthma remission
Male 68 (38/56)
Current or past cigarette smoking by study participant
at 18 years#%(n/N)
43 (22/51)
Acetaminophen use/month at 18 years (median) (p)§ 0 (0, 1)
Atopy at 18 43 (13/30)
Rhinitis at age 18 34 (19/56)
General Terms.
%(n/N) percentage determined from number of participants with condition/total nu
#This includes cigarette smoking by study participants both current and those who
§Number of times acetaminophen used over last 12 months.
¶Number of times Non-Steroidal Anti-inflammatory drugs used over last 12 monthsfactors and pathophysiological characteristics. In our
study, those with clinical remission had the lowest in-
flammatory cell counts but they were not different
from adolescents with never asthma in terms of lung
function, BHR or FeNO, thus seem to have near
“complete remission”. Additional questions on the
age at which asthma stopped revealed that each indi-
vidual experienced remission for a minimum duration
of 3 years at the 18-year follow-up.Persistent asthma Odds ratio 95% Confidence interval p-value
53 (66/125) 1.9 1.0 – 3.6 0.06
58 (70/120) 0.5 0.3 – 1.1 0.07
2 (0, 4) 0.8 0.7 – 1.0 0.04
75 (73/97) 0.3 0.1 – 0.6 0.002
74 (92/125) 0.2 0.1 – 0.4 <0.001
mber of participants with available information on the variable.
have ever smoked cigarettes at any time in the past.
.
Table 6 Adolescent and childhood factors associated with adolescent asthma remission as compared to asthma
persistence (Final model)
Factor Odds ratio 95% Confidence interval p-value
Predictive factors
Male sex 0.3 0.1 – 0.7 0.005
Bronchial reactivity at 10 years 0.3 0.1 – 0.9 0.03
Adolescent factors
Number of times acetaminophen used per month 0.4 0.2 – 0.8 0.008
Rhinitis at age 18 0.2 0.1 – 0.6 0.004
Gain in small to mid-sized airway function (FEF25–75%) between 10 and 18 years 1.7 1.0 – 2.9 0.04
-
Notes:
Odds ratios for remission to persistent asthma are presented by multivariate logistic regression analysis was used with significance determined at p < 0.05.
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cides with the age at which most adolescents report losing
their asthma symptoms [25]. A higher gain in lung function
over adolescence is associated with remission in atopic
asthmatics [5]. We may have only seen this in males
because our baseline measure of airway function was taken
at 10 years when many female participants would already
have entered their pubertal growth spurt, unlike the male
participants. We have extended these lung function find-
ings to investigate other factors that might have an in-
fluence and show that the association between lung
function and remission is independent of atopy, as well as
gender, smoking and early life risk factors (Table 6). We
also found a low BHR at age 10 predicting remission. As
airway reactivity is inversely associated with airway caliber
[26], our observed decrease in BHR in asthma remission
with improved airway function over adolescence, suggests a
means by which airway growth contributes towards asthma
remission. Our findings are consistent with a previous
report of childhood BHR predicting adolescent remission
of asthma [27]. Overall, less severe disease (in term of
symptoms and BHR) at age 10 promotes remission. We
also found that taking acetaminophen during adolescence
was associated with persistence of asthma. There is consi-
derable epidemiological evidence that supports an asso-
ciation between acetaminophen use in pregnancy and early
infancy with asthma in later childhood [28]. Acetamino-
phen may exert its effect by increasing oxidative damage of
the airway epithelium and thus favors persistence. However,
the cause and effect relationship is not clear and the possi-
bility of confounding by indication and reverse causation
remains a potential explanation of our reported association
of lower acetaminophen use with asthma remission.
Sputum eosinophils are considered a hallmark of atopic
asthma [29]. Eosinophil counts in induced sputum correl-
ate with asthma severity in both treated and untreated
subjects [30]. A sputum eosinophil count of more than 2
or 2.5% is regarded as indicative of eosinophilic asthma
[31,32]. This is relevant clinically in terms of treatmentresponses [32]. Using this cut-off, there was evidence of
eosinophilic-derived inflammation in those with
adolescent-onset asthma (eosinophils 3%). Surprisingly,
evidence of sputum eosinophils was less pronounced in
those with persistent asthma (eosinophils 1%) with no
significant differences found when compared to never
asthma, while eosinophil count was significantly higher
in adolescent-onset asthma compared to never asthma
(eosinophils 0.3%). Corticosteroid treatment can suppress
airway eosinophils, however, we did not find any differ-
ence in the proportion taking inhaled corticosteroids in
the persistent asthma compared to the adolescent-onset
asthma (Table 5). Wasserman et al. in a recent cross-
sectional study showed that asthma remission is associated
with reduced inflammation with low eosinophil counts
and ECP as well as reduction in both T helper (h)1 (inter-
leukin (IL)-12, IFN-γ) and Th2 cytokines (IL-5) [33]. How-
ever, contrary to our findings, they did not find differences
in total cell count between asthma remission and never
asthma. Moreover, they found high eosinophils in the
continuing (persistent) asthma groups, while we found spu-
tum eosinophils to be prominent in the adolescent-onset
asthma, but this group was not included in their study.
The main feature of the asthma remission was a pauci-
cellular sputum with very low total cell count. This low
total cell count (lower than never asthma) could be indi-
cative of an overall low level of airway inflammation and
cellular infiltration driving remission of asthma. Specific-
ally, eosinophil counts were very low at 0.3% and the eo-
sinophil/neutrophil ratio in asthma remission (median
0.01) was 3-fold lower than never asthma (median 0.03)
and 30-fold lower than adolescent-onset asthma (median
0.3). Further, FeNO, a marker of eosinophilic inflamma-
tion, was lower in asthma remission than persistent
asthma (Table 3) and same as never asthma (Table 4).
Conclusions
Asthma remission was associated with less severe dis-
ease before adolescence (low symptoms and BHR), male
Figure 2 The total and differential cell counts presented as scatter-plots for various asthma groups.
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low airway cellular infiltrate, while asthma that develops
during adolescence is primarily eosinophilic. Further
studies using bronchial biopsies to correlate findings in
sputum with that occurring in the airway wall are re-
quired to understand the mechanisms associated with
changes in cellular and physiological profiles of asthma
phenotypes during adolescence.
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